Modulating CD27 signaling to treat cancer

Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2012). Modulating CD27 signaling to treat cancer. Oncoimmunology, 1(9), pp. 1604-1606. Austin, Tex.: Landes Bioscience 10.4161/onci.21425

[img] Text
onci%2E21425.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (401kB) | Request a copy

CD27 signaling can either improve T-cell function or lead to T-cell dysfunction, depending on the duration and conditions of receptor ligation. Recent studies have shown that modulating the CD70-CD27 interaction is an attractive strategy to treat solid tumors and also to directly target leukemia stem cells.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Service Sector > Institute of Pathology > Autopsy
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Riether, Carsten; Schürch, Christian and Ochsenbein, Adrian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2162-4011

Publisher:

Landes Bioscience

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:33

Last Modified:

14 Aug 2015 04:07

Publisher DOI:

10.4161/onci.21425

PubMed ID:

23264908

Web of Science ID:

000316281700018

BORIS DOI:

10.7892/boris.12776

URI:

https://boris.unibe.ch/id/eprint/12776 (FactScience: 219247)

Actions (login required)

Edit item Edit item
Provide Feedback